SPY326.54-3.44 -1.04%
DIA265.06-1.53 -0.57%
IXIC10,911.59-274.00 -2.45%

Morgan Stanley Maintains Overweight on Cytokinetics, Lowers Price Target to $24

Morgan Stanley maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $35 to $24.

· 10/12/2020 08:02
Morgan Stanley maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $35 to $24.